Theratechnologies Inc T.TH

NGM down 70% pre-market

[SPCEO1]

Remember NGM at one point seemed like a great bet given its partnerships with Merck in cancer . Then it abandoned NASH after some trial results that did not seem horrendous. Now it has had a bad cancer trial and the stock is being torched. 

I have not payed any attention to it over the last couple of years so I don't know any of the details, but it goes to show once again that even a company with a lot seemingly going for it can flop. Drug research is hard and complicated.

[Biobob]

Well it works both way... Th1902 had maybe 25% downside in the price atm and 100%+ upside in the shorterm and 10 bagger potential in the medium term.. and we shall see once where there in the long term...

[Wino115]

Accept the point, but important to note the NGM drug was for a rare ocular disease and it was not a similar type of construct or approach to an oncology PDC or even ADC. Just don't want folks here to look at that as a direct analogy around PDCs as opposed to the general biotech trial analogy that it is.  I still like the fact that we appear to have safety issues within normal boundaries

[SPCEO1]

Sorry, I was not even aware NGM had an ocular drug. Ithought they were all about cancer after they exited NASH. Why would the stock get so torched on the ocular drug - have their cancer drugs also gone by the wayside in the last coouple of years? I just ahve not been paying much attention to NGM. On safety, and really on every aspect of TH-1902, we only have a very selected and narrow group of

[qwerty22]

From what little I read they'd repositioned themselves as an ophthalmology company and that had a pending buy in from Merck.

[jeffm34]

Interesting insider transactions.  One of the directors believed in the company and got burned.  https://finance.yahoo.com/screener/insider/GOEDDEL%20DAVID%20V